Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




New Way to Treat Chronic Pain Shows Promise

By HospiMedica staff writers
Posted on 18 May 2004
In a series of animal studies, scientists have demonstrated the therapeutic potential of selectively deleting specific nerve cells from the nervous system that convey severe chronic pain. More...
Their findings were published in the May 1, 2004, issue of the Journal of Clinical Investigation.

The treatment was used on eight dogs severely affected by osteroarthritis, cancer, or both. All eventually became more active and later walked with slight or no limps. None showed any adverse side effects from the treatment and their need for other pain-controlling medications was eliminated or greatly reduced. The researchers also selectively deleted the nerve cells called C-fiber neurons from various human neurons cultured together in the laboratory, an indication that the strategy might work in people. C-fibers convey sensations of noxious heat and certain inflammatory signals to the central nervous system.

The treatment is based on using an old drug called resiniferatoxin (RTX) a new way. RTX attaches to a protein called vanilloid receptor 1(VR1), displayed on the surface of certain types of heat-pain-sensing neurons, and prompts a brief influx of calcium through a channel but only in those cells that manufacture the ion channel. This RTX-induced flow of calcium can overdose, seriously disable, and ultimately kill these neurons. By applying RTX directly to the dorsal root ganglia, the scientists knew they could selectively delete specific neurons, such as C-fibers, that exhibit large amounts of VR1 protein. This led to the idea of permanently turning off their chronic pain signals.

"We realized that by focusing on RTX's ability to kill cells, we could apply it therapeutically,” said lead author Dr. Laszlo Karai, a scientist at the U.S. National Institute of Dental and Craniofacial Research (NIDCR, Bethesda, MD, USA). "The technique selectively deletes certain neurons but leaves other untouched.”





Related Links:
National Institute of Dental and Craniofacial Research

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
MRI System
nanoScan MRI 3T/7T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.